Creve Coeur Pharmacy and Owner to Pay $1.4 Million for Ignoring Signs of Illegal Drug Prescriptions
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • Creve Coeur Pharmacy and Owner to Pay $1.4 Million for Ignoring Signs of Illegal Drug Prescriptions

Creve Coeur Pharmacy and Owner to Pay $1.4 Million for Ignoring Signs of Illegal Drug Prescriptions

October 04, 2021
|
Share Article
|
Download Press Release
For Immediate Release
Contact:
Phone Number: (571) 362-5149

ST. LOUIS – Olive Street Pharmacy, LLC, and pharmacy technician Irina Shlafshteyn, agreed to pay $1,507,808.50 to resolve a civil complaint bringing claims under the False Claims Act and Controlled Substances Act related to the unlawful dispensing of controlled substances, including some that were submitted to Medicaid or Medicare for reimbursement. 

According to the civil complaint, Olive Street, a retail pharmacy located in Creve Coeur, Missouri, and Shlafshteyn, partial owner and managing employee, repeatedly dispensed prescriptions for controlled substances while disregarding warning signs of diversion, or “red flags,” indicating the prescriptions were not legitimate. The types of red flags that Olive Street and Shlafshteyn ignored included clear instances of tampering with written prescriptions; dangerous combinations of drugs commonly sought after for recreational purposes; and amounts of opioids that exceeded CDC guidance by as much as 17.5 times the recommended maximum daily dosage.

The complaint also accused Olive Street of routinely dispensing prescriptions for Subsys, an oral fentanyl spray, which is subject to heightened FDA restrictions and indicated only for opioid-tolerant patients experiencing breakthrough pain due to cancer. Olive Street and Shlafshteyn knowingly dispensed high dosages of Subsys to patients who did not qualify for the drug, and that the vast majority of the Subsys Olive Street dispensed was prescribed by Philip Dean, M.D., a Warrenton, Missouri, neurologist, who pleaded guilty to illegally distributing prescription opioids in 2018, including to women with whom he had lived and with whom he had had personal relationships.

Shlafshteyn knew Dean was having intimate relationships with at least one of the women for whom he was prescribing controlled substances. Shlafshteyn and others at her direction continued to dispense Dean’s controlled substance prescriptions to that patient and to other patients of Dean. As the managing employee of Olive Street, Shlafshteyn had the control and authority to effect compliance with the federal regulations.

“Medical professionals have the legal obligation to ensure the dispensing of prescriptions are for legitimate medical purposes,” said Inez Davis, the Drug Enforcement Administration’s Diversion Program Manager for the states of Missouri and Kansas, and southern Illinois. “In this case, the pharmacy abandoned its corresponding responsibility and ignored the clear signs that powerful medications, like oral fentanyl spray, were being prescribed far beyond the recommended guidance. This settlement sends a message that DEA will not accept actions that put people’s lives at risk.”

Shlafshteyn surrendered her Missouri pharmacy technician license effective Sept. 30, 2021, and Olive Street terminated its enrollment in the Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy (TIRF REMS) Program, the FDA-mandated program that had allowed Olive Street to dispense immediate-release fentanyl drugs like Subsys. 

Under the settlement agreement, Shlafshteyn is excluded from participating in the federal healthcare programs for a period of 10 years, and Olive Street is bound by the terms of a corporate integrity agreement governing its ability to continue participating in the federal programs.

The DEA investigated this case with the Office of Inspector General of the Department of Health and Human Services, the Federal Bureau of Investigation and the Missouri Attorney General’s Medicaid Fraud Control Unit.

Download Press Release
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

Michael A. Davis Special Agent in Charge - St. Louis
@DEAStLouisDiv
  • Facebook
  • X
  • Email
  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster

United States Drug Enforcement Administration

Back
  • Who We Are
  • What We Do
  • Careers
  • Resources
Back
  • About
  • Mission
  • History
  • Divisions
  • DEA Museum
  • Wall of Honor
  • Contact Us
Back
  • Domestic Divisions
  • Foreign Divisions
  • Operational Divisions
Back
  • Submit a Tip
  • Extortion Scam
  • Public Affairs
  • Social Media Directory
Back
  • Forensic Sciences
  • Law Enforcement
  • Education and Prevention
  • Drug Information
  • News
  • Campaigns
Back
  • GUARDS
  • Forensic Sciences Policy
  • Forensic Science Organizations
  • Forensic Science Contact
Back
  • DEA Office of Training
  • El Paso Intelligence Center (EPIC)
  • Intelligence
  • Operations
Back
  • Office of Training Programs
Back
  • Administrative Law Judges
  • DEA Asset Forfeiture
  • Domestic Cannabis Suppression / Eradication Program
  • HIDTA
  • OCDETF
Back
  • Family Summit
  • Red Ribbon
  • Kiki and the History of Red Ribbon Week
  • Red Ribbon Toolkit - Resources For Your Community
  • DEA’s Family Summit
  • Operation Engage
  • Community Outreach
  • Just Think Twice
  • Campus Drug Prevention
  • Get Smart About Drugs
  • Operation Prevention
Back
  • Drug Policy
  • Drug Scheduling
  • The Controlled Substances Act
Back
  • Alerts
  • Press Releases
  • Most Wanted Fugitives
  • Stories
  • Events
  • Speeches
  • Testimony
Back
  • All Fugitives
Back
  • One Pill Can Kill
  • DEA National Prescription Drug Take Back Day
Back
  • Senior Citizens
  • Partner Toolbox
  • Social Media Campaign
Back
  • Special Agent
  • Diversion Investigator
  • Intelligence Research Specialist
  • Forensic Sciences Careers
  • Professional & Administrative Careers
  • Student & Entry Level Careers
  • Employment Eligibility
  • How to Apply
Back
  • Special Agent FAQs
Back
  • Diversion Investigator Job Announcement
Back
  • Intelligence Research Specialist Job Announcements
  • Intelligence Research Specialists FAQs
  • Schedule A Hiring Authority: Intelligence Research Specialist
Back
  • How To Claim Veterans' Preference
  • Priority Consideration
  • Benefits
  • Veterans and People With Disabilities
  • Operation Warfighter
Back
  • Illegal Online Pharmacies
  • OD Justice
  • Fentanyl Supply Chain
  • Pill Press Resources
  • Recovery Resources
  • Together for Families
  • Data and Statistics
  • FOIA
  • Publications
  • Media Galleries
  • Victim Witness Assistance Program
Back
  • Domestic Arrests
  • Staffing and Budget
Back
  • About FOIA
  • Contact DEA FOIA
  • Make a Request
  • What Happens After Making a Request
  • Requester Categories
  • Fees Charged
  • Fee Waiver
  • FOIA FAQ
  • FOIA Logs and Reports
  • FOIA Library
  • Additional FOIA Links
  • FOIA Exemptions
  • What Are Exclusions?
  • Privacy Act
  • Privacy Act Exemptions
  • Privacy Impact Assessment and Management Information Systems
Back
  • Victim Witness Assistance Program Resources
  • Human Trafficking Prevention
  • Submit A Tip +
  • Get Updates
  • Scam Alert
    • English
    • Español